Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) released its quarterly earnings data on Tuesday. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.06, Zacks reports. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft updated its FY 2026 guidance to 1.200-1.346 EPS.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY traded up $0.35 during trading hours on Tuesday, reaching $13.92. 73,732 shares of the company traded hands, compared to its average volume of 1,249,245. The stock’s fifty day moving average is $12.36 and its 200 day moving average is $12.08. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05. Bayer Aktiengesellschaft has a 1-year low of $7.19 and a 1-year high of $15.23. The stock has a market cap of $54.71 billion, a P/E ratio of -21.75, a price-to-earnings-growth ratio of 4.46 and a beta of 0.55.

Wall Street Analyst Weigh In

Several research firms have weighed in on BAYRY. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.